Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript
Thanks, operator. Thank you for joining us for Exact Sciences' third-quarter 2024 conference call. On the call today are ...
Exact Sciences Announces Third-Quarter 2024 Results
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
Exact Sciences (NASDAQ:EXAS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target boosted by stock analysts at Canaccord Genuity Group from ...
Exact Sciences (NASDAQ:EXAS) Shares Gap Down on Disappointing Earnings
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...
Exact Sciences: Long-Term Growth Prospects Intact Despite Short-Term Challenges
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Exact Sciences Poised for Recovery and Long-Term Growth Amidst Challenges
Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...
Benzinga.com5d
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates
Read Next: Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race Outlook: Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion ...
Investing5d
Exact Sciences stock target cut by Benchmark, retains Buy rating
Baird maintained an Outperform rating on Exact Sciences but reduced the stock's price target from $70.00 to $67.00. The adjustment came after the company reported third-quarter revenue that fell ...
Exact Sciences Stock Falls After Cutting Outlook, Posting Lower-Than-Expected 3Q Results
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.